KYNB

1.56014.75%
TW

Thane Wettig

CEO & Director

Mr. Thane Wettig serves as Director of Kyntra Bio, Inc. (formerly known as FibroGen, Inc.) since October 2, 2023. He serves as Chief Executive Officer at Kyntra Bio, Inc. (formerly known as FibroGen, Inc.) since October 2, 2023 and served as Interim Chief Executive Officer since July 23, 2023 until October 2, 2023 and served as its Executive Vice President & Chief Commercial Officer since September 2022 until July 22, 2023. He had been Chief Commercial Officer at Intarcia Therapeutics, Inc. since November 2019. He served as Chief Marketing Officer and Metabolic Franchise Head at Intarcia Therapeutics Inc. since July 3, 2018 until November 2019 and also served as its Vice President. Mr. Wettig has global biopharmaceutical leadership and commercial experience. Mr. Wettig has extensive diabetes marketing experience to Intarcia. In his most recent role, he served as the Chief Marketing Officer for Lilly Diabetes, Eli Lilly & Co.'s largest therapeutic area, where he led a team of more than 60 professionals responsible for new product development, brand management, market research and market access. He has extensive experience in the creation, launch and evolution of multiple blockbuster diabetes brands and delivery devices including Humalog, Byetta, Bydureon, Trajenta, Jardiance, Trulicity and Basaglar. He also served as the commercial lead for the negotiation, structure and ongoing management of the Lilly/Boehringer-Ingelheim diabetes alliance. He served as Vice President of Global Marketing, Strategy and Alliance Management for Lilly Diabetes. He began his career at Lilly 1990. He began his career as a primary care sales rep, where he established himself as a top performer, and gained additional leadership and general management experiences in business development, sales leadership and Lilly's German operation. Mr. Wettig received his M.B.A. and B.A. in biology from Washington University in St. Louis.

Positions